Through genetic and pharmacologic approaches, our studies delineate the requirement of USP15 in AML through its rewiring of oxidative stress sensing and reveal the tractability of USP15 as a potential therapeutic target in AML. The gene discussed is USP15; the disease is acute myeloid leukemia.